← Back to guidelines
Cardiology1 paper

Disorder of truncal valve prosthesis

Last edited: 4/23/2026

Overview

Recurrent systemic embolic events are a significant complication following truncal valve prosthesis, often leading to severe morbidity and mortality. These events frequently recur, particularly in patients with specific risk factors including mitral prostheses, preoperative atrial fibrillation, left atrial enlargement, and inadequate anticoagulation 1.

Diagnosis

  • Clinical Presentation: Recurrent systemic emboli manifest as acute ischemic events (e.g., stroke, limb ischemia) 1.
  • Imaging: Echocardiography to assess prosthesis function and detect thrombosis 1.
  • Laboratory Tests: Evaluate coagulation profiles and monitor anticoagulant levels 1.
  • Pathological Studies: Prosthesis explantation and histopathological examination if recurrent emboli are suspected 1.
  • Management

  • Anticoagulation Therapy: Optimal anticoagulation is crucial; poor therapy significantly increases recurrence risk (60% vs 20% at 54 months) 1.
  • Target INR: Maintain INR within therapeutic range (typically 2.0-3.0 for mechanical valves) 1.
  • Device Evaluation: Regular follow-up echocardiograms to monitor prosthesis function and detect thrombosis early 1.
  • Risk Factor Management: Address underlying conditions like atrial fibrillation and left atrial enlargement 1.
  • Special Populations

  • Elderly: Increased risk due to comorbidities like atrial fibrillation and left atrial enlargement; careful anticoagulation management is essential 1.
  • Comorbidities: Preoperative atrial fibrillation and left atrial enlargement elevate embolic risk; tailored anticoagulation strategies are recommended 1.
  • Key Recommendations

  • Optimize Anticoagulation: Ensure adequate anticoagulation therapy to significantly reduce recurrence of embolic events (Evidence: Moderate) 1.
  • Regular Monitoring: Implement frequent echocardiographic monitoring to detect early signs of prosthesis thrombosis (Evidence: Moderate) 1.
  • Identify and Manage Risk Factors: Screen for and manage risk factors such as atrial fibrillation and left atrial enlargement to mitigate embolic risk (Evidence: Moderate) 1.
  • References

    1 Acar J, Enriquez-Sarano M, Farah E, Kassab R, Tubiana P, Roger V. Recurrent systemic embolic events with valve prosthesis. European heart journal 1984. link

    Original source

    1. [1]
      Recurrent systemic embolic events with valve prosthesis.Acar J, Enriquez-Sarano M, Farah E, Kassab R, Tubiana P, Roger V European heart journal (1984)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG